Brian Pereira
Chief Executive Officer at VISTERRA INC
Net worth: 4 M $ as of 29/04/2024
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Michael Amoroso | M | 46 | 4 years | |
T. Crockett | M | 49 |
KalVista Pharmaceuticals Ltd.
KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | 20 years |
Nikhil Pereira-Kamath | M | - |
Africa Healthcare Network Rwanda Ltd.
Africa Healthcare Network Rwanda Ltd. Medical/Nursing ServicesHealth Services Africa Healthcare Network Rwanda Ltd. operates kidney dialysis centers and hospitals. The company was founded by Nikhil Pereira-Kamath, Brian J.G. Pereira and Lloyd Vincent in 2015 and is headquartered in Kigali, South Africa. | 9 years |
Ben Palleiko | M | 58 | 8 years | |
Lata Krishnan | F | 62 |
American India Foundation
| 23 years |
Tim Bertram | M | 68 |
ProKidney LLC
ProKidney LLC Packaged SoftwareTechnology Services ProKidney LLC develops therapies for kidney disease. The company was founded by Pablo Legorreta and is headquartered in Winston-Salem, NC. | 5 years |
Ed Feener | M | 64 |
KalVista Pharmaceuticals Ltd.
KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | 20 years |
Albert Cha | M | 51 |
Biodel, Inc.
Biodel, Inc. Pharmaceuticals: MajorHealth Technology Biodel, Inc. is a pharmaceutical company, which develops novel formulations of already approved therapeutics to treat endocrine disorders such as diabetes and osteoporosis. The company develops product candidates by applying formulation technologies to existing drugs in order to improve their therapeutic profiles. Biodel was founded by Solomon S. Steiner and Erik Steiner on December 3, 2003 and is headquartered in Danbury, CT.
KalVista Pharmaceuticals Ltd.
KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | 11 years |
Edward Unkart | M | 74 |
KalVista Pharmaceuticals Ltd.
KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | 10 years |
Lloyd Vincent | M | - |
Africa Healthcare Network Rwanda Ltd.
Africa Healthcare Network Rwanda Ltd. Medical/Nursing ServicesHealth Services Africa Healthcare Network Rwanda Ltd. operates kidney dialysis centers and hospitals. The company was founded by Nikhil Pereira-Kamath, Brian J.G. Pereira and Lloyd Vincent in 2015 and is headquartered in Kigali, South Africa. | - |
Chris Kiefer | M | - | 7 years | |
Bruce Culleton | M | 57 | 1 years | |
Todd Curtis | M | - | 9 years | |
Robert Haigh | M | 64 |
KalVista Pharmaceuticals Ltd.
KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | 13 years |
Greg Gin | M | - | 4 years | |
Patrick Treanor | M | - | 2 years | |
Libbie McKenzie | M | 51 |
ProKidney LLC
ProKidney LLC Packaged SoftwareTechnology Services ProKidney LLC develops therapies for kidney disease. The company was founded by Pablo Legorreta and is headquartered in Winston-Salem, NC. | 2 years |
José Ignacio Jiménez Santos | M | 49 | - | |
Christopher Yea | M | 61 |
KalVista Pharmaceuticals Ltd.
KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | 9 years |
Matt Williams | M | - |
Africa Healthcare Network Rwanda Ltd.
Africa Healthcare Network Rwanda Ltd. Medical/Nursing ServicesHealth Services Africa Healthcare Network Rwanda Ltd. operates kidney dialysis centers and hospitals. The company was founded by Nikhil Pereira-Kamath, Brian J.G. Pereira and Lloyd Vincent in 2015 and is headquartered in Kigali, South Africa. | 2 years |
Deepak Jain | M | 70 |
ProKidney LLC
ProKidney LLC Packaged SoftwareTechnology Services ProKidney LLC develops therapies for kidney disease. The company was founded by Pablo Legorreta and is headquartered in Winston-Salem, NC. | 8 years |
Jennifer Fox | F | 53 | 2 years | |
Rachel Morten | F | - | 8 years | |
Uma Sinha | M | 67 | - | |
Stephen Gerard Donnelly | M | - |
KalVista Pharmaceuticals Ltd.
KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | - |
James Coulston | M | 48 |
ProKidney LLC
ProKidney LLC Packaged SoftwareTechnology Services ProKidney LLC develops therapies for kidney disease. The company was founded by Pablo Legorreta and is headquartered in Winston-Salem, NC. | 5 years |
Pablo Legorreta | M | 60 |
ProKidney LLC
ProKidney LLC Packaged SoftwareTechnology Services ProKidney LLC develops therapies for kidney disease. The company was founded by Pablo Legorreta and is headquartered in Winston-Salem, NC. | 2 years |
Nancy Stuart | F | 65 | 3 years | |
Bill Doyle | M | 61 | 2 years | |
Ajaypal Banga | M | 65 |
American India Foundation
| 8 years |
Richard H. Aldrich | M | 69 |
KalVista Pharmaceuticals Ltd.
KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | 4 years |
Victor J. Menezes | M | - |
American India Foundation
| - |
Satjiv Chahil | M | 72 |
American India Foundation
| - |
Alan Lotvin | M | 62 | 2 years | |
John Maraganore | M | 60 | 2 years | |
Todd Girolamo | M | 59 | 2 years | |
Manu Anand | M | 64 |
American India Foundation
| - |
Nimish Patel | M | - |
American India Foundation
| - |
Harren Jhoti | M | - | - | |
Toshiki Sudo | M | - | - | |
Greg Babcock | M | - | 11 years | |
Joseph Stavas | M | 69 | 5 years | |
Ritu Chugh | F | - |
American India Foundation
| - |
Nita Gangwal | F | - |
American India Foundation
| - |
Arjun Sanyal | M | - |
American India Foundation
| - |
Tania Mirchandani | F | - |
American India Foundation
| - |
Kumar Malavalli | M | - |
American India Foundation
| - |
Harit Talwar | M | 63 |
American India Foundation
| - |
Dinesh C. Paliwal | M | 67 |
American India Foundation
| 12 years |
Jarrod Aldom | M | - | - | |
Pradeep Kashyap | M | - |
American India Foundation
| - |
Burns McClellan | M | - | - | |
Sanjay Sinho | M | - |
American India Foundation
| - |
Adil Siraj Zainulbhai | M | 70 |
American India Foundation
| - |
Ravindranath Akhoury | M | 77 |
American India Foundation
| - |
Saurabh Srivastava | M | 78 |
American India Foundation
| - |
Rohit Kapoor | M | 59 |
American India Foundation
| 6 years |
Ajay Shah | M | 64 |
American India Foundation
| - |
Mike Smith | M | - | 8 years | |
Neeti Khaitan | F | - |
American India Foundation
| - |
Kailash Joshi | M | - |
American India Foundation
| - |
Vivek Chopra | M | - |
American India Foundation
| - |
Lloyd Paul Aiello | M | - |
KalVista Pharmaceuticals Ltd.
KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | 13 years |
Sumir Chadha | M | 53 |
American India Foundation
| - |
Zachary Shriver | M | 50 | 15 years | |
Raj Seshadri | F | 58 |
American India Foundation
| 5 years |
Darin Weber | M | 56 | 4 years | |
Raj Bhatia | M | - |
American India Foundation
| - |
Neil Herson | M | - |
Africa Healthcare Network Rwanda Ltd.
Africa Healthcare Network Rwanda Ltd. Medical/Nursing ServicesHealth Services Africa Healthcare Network Rwanda Ltd. operates kidney dialysis centers and hospitals. The company was founded by Nikhil Pereira-Kamath, Brian J.G. Pereira and Lloyd Vincent in 2015 and is headquartered in Kigali, South Africa. | - |
Robert McQuade | M | 67 | - | |
Venkat Srinivasan | M | - |
American India Foundation
| - |
Derek Chen Brand | M | - |
Africa Healthcare Network Rwanda Ltd.
Africa Healthcare Network Rwanda Ltd. Medical/Nursing ServicesHealth Services Africa Healthcare Network Rwanda Ltd. operates kidney dialysis centers and hospitals. The company was founded by Nikhil Pereira-Kamath, Brian J.G. Pereira and Lloyd Vincent in 2015 and is headquartered in Kigali, South Africa. | - |
Kelechi Ohiri | M | - |
Africa Healthcare Network Rwanda Ltd.
Africa Healthcare Network Rwanda Ltd. Medical/Nursing ServicesHealth Services Africa Healthcare Network Rwanda Ltd. operates kidney dialysis centers and hospitals. The company was founded by Nikhil Pereira-Kamath, Brian J.G. Pereira and Lloyd Vincent in 2015 and is headquartered in Kigali, South Africa. | - |
Shigeru Handa | M | - |
Africa Healthcare Network Rwanda Ltd.
Africa Healthcare Network Rwanda Ltd. Medical/Nursing ServicesHealth Services Africa Healthcare Network Rwanda Ltd. operates kidney dialysis centers and hospitals. The company was founded by Nikhil Pereira-Kamath, Brian J.G. Pereira and Lloyd Vincent in 2015 and is headquartered in Kigali, South Africa. | - |
Jean Bender | F | - | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Frank Thomas | M | 54 | 6 years | |
Jerome Goldstein | M | 84 | 26 years | |
David Arkowitz | M | 62 | 10 years | |
Solomon Steiner | M | 86 |
Biodel, Inc.
Biodel, Inc. Pharmaceuticals: MajorHealth Technology Biodel, Inc. is a pharmaceutical company, which develops novel formulations of already approved therapeutics to treat endocrine disorders such as diabetes and osteoporosis. The company develops product candidates by applying formulation technologies to existing drugs in order to improve their therapeutic profiles. Biodel was founded by Solomon S. Steiner and Erik Steiner on December 3, 2003 and is headquartered in Danbury, CT. | 8 years |
Scott A. Holmes | M | 50 | 4 years | |
Davey Scoon | M | 78 |
Biodel, Inc.
Biodel, Inc. Pharmaceuticals: MajorHealth Technology Biodel, Inc. is a pharmaceutical company, which develops novel formulations of already approved therapeutics to treat endocrine disorders such as diabetes and osteoporosis. The company develops product candidates by applying formulation technologies to existing drugs in order to improve their therapeutic profiles. Biodel was founded by Solomon S. Steiner and Erik Steiner on December 3, 2003 and is headquartered in Danbury, CT. | 14 years |
Mark Stejbach | M | 61 | 4 years | |
Michael Narachi | M | 64 | 8 years | |
Joao Siffert | M | 60 | 2 years | |
Joseph Farmer | M | 52 | - | |
Gerard Michel | M | 60 |
Biodel, Inc.
Biodel, Inc. Pharmaceuticals: MajorHealth Technology Biodel, Inc. is a pharmaceutical company, which develops novel formulations of already approved therapeutics to treat endocrine disorders such as diabetes and osteoporosis. The company develops product candidates by applying formulation technologies to existing drugs in order to improve their therapeutic profiles. Biodel was founded by Solomon S. Steiner and Erik Steiner on December 3, 2003 and is headquartered in Danbury, CT. | 7 years |
Errol de Souza | M | 70 |
Biodel, Inc.
Biodel, Inc. Pharmaceuticals: MajorHealth Technology Biodel, Inc. is a pharmaceutical company, which develops novel formulations of already approved therapeutics to treat endocrine disorders such as diabetes and osteoporosis. The company develops product candidates by applying formulation technologies to existing drugs in order to improve their therapeutic profiles. Biodel was founded by Solomon S. Steiner and Erik Steiner on December 3, 2003 and is headquartered in Danbury, CT. | 6 years |
Stephen B. Howell | M | 79 | 24 years | |
Timothy G. Healey | M | 58 | - | |
Ron Zwanziger | M | 70 | 5 years | |
Mark Alvino | M | 56 | 14 years | |
Robert Perez | M | 59 | 11 years | |
Joseph Vincent Bonventre | M | 74 | 5 years | |
Will Price | M | - |
Kellogg School of Management
| 2 years |
Amy Sullivan | F | 54 | - | |
Stefano Buono | M | 57 | 2 years | |
Shane McCarthy | M | - |
Kellogg School of Management
| 3 years |
Paul Mann | M | 48 | - | |
Parvinder S. Hyare | M | - | - | |
Richard van Dyune | M | 70 | 2 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 91 | 91.00% |
United Kingdom | 9 | 9.00% |
South Africa | 7 | 7.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Brian Pereira
- Personal Network